

Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France

Appendix

Contents

| | |
|---|---|
| Selection of individuals..... | 1 |
| Epidemiological background | 2 |
| Descriptive and univariate analysis | 3 |
| Univariate analysis | 4 |
| Multivariate analysis..... | 5 |

Selection of individuals

Table S1 : Inclusion process (before matching)

| | Excluded | Remain |
|--|----------|----------------|
| Born in 1962 and earlier and boosterized during the inclusion period | 878,492 | |
| Exclusion for data inconsistency | 10,354 | 868,138 |
| very-high-risk comorbidity ¹ | 91,686 | 773,623 |
| primary vaccine series with less or more than two doses | 47,565 | 728,887 |
| at least one supplementary dose for medical reason (ex: immunosuppression) | 24,889 | 703,998 |
| pre-inclusion booster with non mRNA vaccine | 113 | 703,885 |
| positive test < 60 days before follow-up | 1,861 | 702,024 |
| >20 tests in the 6 months prior to inclusion | 26 | 701,998 |
| over 99 years | 1,940 | 700,058 |

¹ : cancers, haematological malignancies undergoing chemotherapy, severe chronic kidney disease, chronic dialysis, solid organ transplants, haematopoietic stem cell allografts, chronic multi-disease conditions with two or more organ failures, certain rare diseases and those at particular risk of infection, and Down's syndrome

Table S2 : Size of the study population after matching

| | Total | matched | % matched |
|-----------------|---------|---------|-----------|
| Original/BA.4-5 | 582,398 | 68,426 | 12% |
| Original | 117,660 | 68,426 | 58% |
| Total | 697,649 | 136,852 | 20% |

Epidemiological background

Figure S1: Weekly community incidence rates (France, data SI-DEP)






Figure S2: Emergence of B.Q.1.1* in France according to representative whole genome sequencing



Descriptive and univariate analysis

Figure S3 : Immunisation history by rank of booster at inclusion (one colour per dose: salmon: dose 1, pink: dose 2, blue: dose 3, light blue: dose 4, green: dose 5)



Univariate analysis

Tableau S3 : Descriptive statistics by occurrence of the outcome

| | Outcome | | p-value ² |
|---------------------------|------------------------------|-----------------------------|----------------------|
| | No, N = 134,680 ¹ | Yes, N = 2,172 ¹ | |
| Week of inclusion | | | <0.001 |
| 2022-W40 | 20,097 (98%) | 391 (2%) | |
| 2022-W41 | 51,672 (98%) | 898 (2%) | |
| 2022-W42 | 33,367 (99%) | 507 (1%) | |
| 2022-W43 | 19,921 (99%) | 253 (1%) | |
| 2022-W44 | 9,623 (99%) | 123 (1%) | |
| Inclusion booster | | | 0.008 |
| Original | 67,279 (98%) | 1,147 (2%) | |
| Original / BA.4-5 | 67,401 (99%) | 1,025 (1%) | |
| Booster dose at inclusion | | | <0.001 |
| 1 | 3,126 (99%) | 46 (1%) | |
| 2 | 114,593 (98%) | 1,767 (2%) | |
| 3 | 16,961 (98%) | 359 (2%) | |
| Sex | | | <0.001 |
| Female | 73,552 (99%) | 1,092 (1%) | |
| Male | 61,128 (98%) | 1,080 (2%) | |
| Age | | | 0.89 |
| 60-79 | 99,319 (98%) | 1,599 (2%) | |
| 80-99 | 35,361 (98%) | 573 (2%) | |
| Previous infection | | | <0.001 |
| Undocumented | 92,126 (98%) | 1,791 (2%) | |
| Delta/Pre-Delta | 2,678 (98%) | 61 (2%) | |
| Tr_Delta-BA.1 | 1,708 (98%) | 28 (2%) | |
| Omicron BA.1 | 11,925 (99%) | 158 (1%) | |
| Omicron BA.2 BA.4/5 | 26,243 (99%) | 134 (1%) | |
| Medium-risk comorbidity | | | 0.003 |
| No | 86,249 (98%) | 1,323 (2%) | |
| Yes | 48,431 (98%) | 849 (2%) | |

¹n (%)

²Pearson's Chi-squared test; Fisher's exact test

Figure S4 : Cumulative probability over time of symptomatic infection since the booster dose by the type of vaccine of the booster dose - Follow-up started 7 days after booster injection; ribbons indicate 95%CI





Figure S5 : Cumulative probability over time of symptomatic infection since the booster dose by previous infection - Follow-up started 7 days after booster injection; ribbons indicate 95%CI



Multivariate analysis

Table S4 : Multivariate analysis (Cox Proportional-Hazards Model - N=136,852, number of events= 2172)

| | aHR ¹ | 95% CI ¹ | p-value |
|-------------------------|------------------|---------------------|---------|
| Inclusion booster | | | |
| Original | — | — | |
| Original / BA.4-5 | 0.92 | 0.84, 1.00 | 0.045 |
| Age | | | |
| 60-79 | — | — | |
| 80-99 | 0.98 | 0.89, 1.08 | 0.6 |
| Sex | | | |
| Female | — | — | |
| Male | 1.19 | 1.09, 1.29 | <0.001 |
| Medium-risk comorbidity | | | |
| No | — | — | |
| Yes | 1.12 | 1.03, 1.23 | 0.008 |
| Previous infection | | | |
| Undocumented | — | — | |
| Delta/Pre-Delta | 1.15 | 0.89, 1.48 | 0.3 |
| Tr_Delta-BA.1 | 0.84 | 0.58, 1.21 | 0.3 |
| Omicron BA.1 | 0.67 | 0.57, 0.79 | <0.001 |
| Omicron BA.2 BA.4/5 | 0.26 | 0.22, 0.31 | <0.001 |

¹aHR = adjusted hazard ratio, CI = Confidence Interval

Table S5 : Multivariate analysis – Participants without previous infection (Cox Proportional-Hazards Model - N=93,917, number of events= 1791)

| | aHR [†] | 95% CI [†] | p-value |
|-------------------------|------------------|---------------------|---------|
| Inclusion booster | | | |
| Original | — | — | |
| Original / BA.4-5 | 0.96 | 0.88, 1.06 | 0.4 |
| Age | | | |
| 60-79 | — | — | |
| 80-99 | 0.90 | 0.81, 1.01 | 0.070 |
| Sex | | | |
| Female | — | — | |
| Male | 1.21 | 1.10, 1.33 | <0.001 |
| Medium-risk comorbidity | | | |
| No | — | — | |
| Yes | 1.12 | 1.02, 1.24 | 0.017 |

[†]aHR = Hazard Ratio, CI = Confidence Interval